Endurance exercise increases skeletal muscle kynurenine aminotransferases and plasma kynurenic acid in humans

American Journal of Physiology - Cell Physiology

Volumn 310, Issue 10, 2016, Pages C836-C840

  Schlittler, Maja ^a,b   Goiny, Michel ^a   Agudelo, Leandro Z ^a   Venckunas, Tomas ^b   Brazaitis, Marius ^b   Skurvydas, Albertas ^b   Kamandulis, Sigitas ^b   Ruas, Jorge L ^a   Erhardt, Sophie ^a   Westerblad, Håkan ^a,b   Andersson, Daniel C ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LITHUANIAN SPORTS UNIVERSITY   (Lithuania)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Endurance exercise; Kynurenic acid; Kynurenine aminotransferases; Skeletal muscle

Indexed keywords

KYNURENIC ACID; KYNURENINE; KYNURENINE AMINOTRANSFERASE; AMINOTRANSFERASE; KYNURENINE-OXOGLUTARATE TRANSAMINASE;

ARTICLE; CONTROLLED STUDY; CYCLING; DEPRESSION; ENDURANCE TRAINING; ENZYME METABOLISM; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; MUSCLE BIOPSY; MUSCLE TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RUNNING; SKELETAL MUSCLE; VASTUS LATERALIS MUSCLE; BLOOD; CONTROLLED CLINICAL TRIAL; ENDURANCE; EXERCISE; METABOLISM; PHYSIOLOGY; PROCEDURES; UPREGULATION; YOUNG ADULT;

EXERCISE; HUMANS; KYNURENIC ACID; MALE; MUSCLE, SKELETAL; PHYSICAL CONDITIONING, HUMAN; PHYSICAL ENDURANCE; TRANSAMINASES; UP-REGULATION; YOUNG ADULT;

EID: 84983792035     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00053.2016     Document Type: Article

References (21)

1. Agudelo LZ, Femenia T, Orhan F, Porsmyr-Palmertz M, Goiny M, Martinez-Redondo V, Correia JC, Izadi M, Bhat M, Schuppe-Koistinen I, Pettersson AT, Ferreira DM, Krook A, Barres R, Zierath JR, Erhardt S, Lindskog M, Ruas JL. Skeletal muscle PGC-1alpha1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell 159: 33–45, 2014.
2. Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Traskman- Bendz L, Guillemin GJ, Erhardt S, Brundin L. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav Immun 43: 110–117, 2015.
3. Chaouloff F. Effects of acute physical exercise on central serotonergic systems. Med Sci Sports Exerc 29: 58–62, 1997.
4. Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimer J, Waugh FR, McMurdo M, Mead GE. Exercise for depression. Cochrane Database Syst Rev 9: CD004366, 2013.
5. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, Lundberg K, Postolache TT, Traskman-Bendz L, Guillemin GJ, Brundin L. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 38: 743–752, 2013.
6. Erhardt S, Olsson SK, Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 23: 91–101, 2009.
7. Fernstrom JD, Fernstrom MH. Exercise, serum free tryptophan, and central fatigue. J Nutr 136: 553S–559S, 2006.
8. Ferrari AJ, Charlson FJ, Norman RE, Flaxman AD, Patten SB, Vos T, Whiteford HA. The epidemiological modelling of major depressive disorder: application for the Global Burden of Disease Study 2010. PLoS One 8: e69637, 2013.
9. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386: 743–800, 2015.
10. Jeppesen J, Kiens B. Regulation and limitations to fatty acid oxidation during exercise. J Physiol 590: 1059–1068, 2012.
11. Kanda K, Sugama K, Hayashida H, Sakuma J, Kawakami Y, Miura S, Yoshioka H, Mori Y, Suzuki K. Eccentric exercise-induced delayedonset muscle soreness and changes in markers of muscle damage and inflammation. Exerc Immunol Rev 19: 72–85, 2013.
12. Kennedy SH, Eisfeld BS, Cooke RG. Quality of life: an important dimension in assessing the treatment of depression? J Psychiatry Neurosci 26, Suppl: S23–S28, 2001.
13. Lawlor DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. BMJ 322: 763–767, 2001.
14. Lewis GD, Farrell L, Wood MJ, Martinovic M, Arany Z, Rowe GC, Souza A, Cheng S, McCabe EL, Yang E, Shi X, Deo R, Roth FP, Asnani A, Rhee EP, Systrom DM, Semigran MJ, Vasan RS, Carr SA, Wang TJ, Sabatine MS, Clish CB, Gerszten RE. Metabolic signatures of exercise in human plasma. Sci Transl Med 2: 33ra37, 2010.
15. Manning JS, Jackson WC. Treating depression in primary care: initial and follow-up treatment strategies. J Clin Psychiatry 76: e5, 2015.
16. Midttun O, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 23: 1371–1379, 2009.
17. Moroni F, Carpenedo R, Cozzi A, Meli E, Chiarugi A, Pellegrini-Giampietro DE. Studies on the neuroprotective action of kynurenine mono-oxygenase inhibitors in post-ischemic brain damage. Adv Exp Med Biol 527: 127–136, 2003.
18. Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12: 988–1000, 2007.
19. Ruas JL, White JP, Rao RR, Kleiner S, Brannan KT, Harrison BC, Greene NP, Wu J, Estall JL, Irving BA, Lanza IR, Rasbach KA, Okutsu M, Nair KS, Yan Z, Leinwand LA, Spiegelman BM. A PGC-1alpha isoform induced by resistance training regulates skeletal muscle hypertrophy. Cell 151: 1319–1331, 2012.
20. Savitz J, Drevets WC, Smith CM, Victor TA, Wurfel BE, Bellgowan PS, Bodurka J, Teague TK, Dantzer R. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 40: 463–471, 2015.
21. Schwieler L, Samuelsson M, Frye MA, Bhat M, Schuppe-Koistinen I, Jungholm O, Johansson AG, Landen M, Sellgren CM, Erhardt S. Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients. J Neuroinflammation 13: 51, 2016.